1. and (1997). Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 63, 565–568.
2. , , , and (1996). Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6, 259–274.
3. , , , and (2012). Viruses and vitamin D in the etiology of type 1 diabetes mellitus and multiple sclerosis. Virus Res., in press.
4. , , , et al. (2000). Transient virus infection and multiple sclerosis. Rev. Med. Virol. 10, 291–303.
5. and (2011). Prevention and treatment of MS: studying the effects of vitamin D. Mult. Scler. J. 17, 1405–1411.
6. , , , , , and . (2011). Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214–219.
7 and (1996). Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 26, 1641–1646.
8. , , and (2000). IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J. Immunol. 164, 2759–2768.
9. , , , et al. (2003). Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744–748.
10. , , , et al. (2006). IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177, 566–573.
11. , , , et al. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240.
12. , , , et al. (1999). Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 5, 101–104.
13. , , and (2006). IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol. 176, 7768–7774.
14. , , ., ., and (2006). A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203, 1685–1691.
15. , , , , and (2009). Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J. Immunol. 183, 1715–1723.
16. (2009). Gammadelta T cell receptors without a job. Immunity 31, 181–183.
17. , , , , , and (2009). Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31, 331–341.
18. , , , , , and (2011). Caspase-1 processed cytokines IL-1β and IL-18 promote IL-17-production by γδ and CD4 T cells that mediate autoimmunity. J. Immunol. 186, 5738–5748.
19. , , , and (2006). Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat. Immunol. 7, 1151–1156.
20. , , , et al. (2007). IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448, 484–487.
21. , , and (2011). New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am. J. Clin. Dermatol. 12, 113–125.
22. , , , et al. (2006). Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 116, 1317–1326.
23. , , , , , and (2008). Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7, 796–804.
24. , , , et al. (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899–910.
25. , , , , and (2005). Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353, 375–381.
26. , , , et al. (2008). Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786–1801.
27. , , , et al. (2001). Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345, 1098–1104.
28. , , , et al. (2011). IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav. Immun. 25, 1170–1181.
29. ., , and . (2009). Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur. J. Immunol. 39, 1108–1117.